

## UNITED STATE EPARTMENT OF COMMERCE United Stat s Patent and Trad mark Office

09/497,822 02/03/00 FRENCH  020792 HM22/0702  MYERS BIGEL SIBLEY & SAJOVEC  PO BOX 37428  RALEIGH NC 27627	F 5470-130  EXAMINER  PAK, M
020792 HM22/0702 PO BOX 37428	F 5470-130
MYERS BIGEL SIBLEY & SAJOVEC PO BOX 37428	EXAMINER
PO BOX 37428 SAJOVEC	DAY M
NHLEIGH NU 27627	1777 7 18
	ART UNIT PAPER NUMB
	1646
	DATE MAILED:

Please find below and/or attached an Office communication concerning this application or

**Commissioner of Patents and Trademarks** 

PTO-90C (Rev. 11/00)

1- File Copy



## DEPARTMENT OF COMMERCE Pat nt and Trad

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

057		Washington, D.C. 20231		
SERIAL NUMBER	FILING DATE	FIRS	T NAMED APPLICANT	ATTORNEY DOCKET NO.
				EXAMINER
			ART UNIT	1 APER NUMBER
		J	DATE MAILED:	

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

Serial No. 09/497,822

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is

Any inquiry concerning this communication or earlier communications from the examiner should be directed 2. to Michael Pak, whose telephone number is (703) 305-7038. The examiner can normally be reached on Monday

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196. Hick PD. Mu

Michael Pak

Primary Patent Examiner

Art Unit 1646 19 June 2001

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by     37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822
and/or unreadable as indicated on the attached CRF Diskette Problem Report: A Substitute
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d).
For questions regarding compliance to these requirements, please contact:  For Rules Interpretation, call (703) 308-4216  For CRF Submission Help, call (703) 308-4212  For Patentln software help, call (703) 308-6856
PI EASE DETUNE

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE